Effectiveness of preoperative micronized purified flavonoid fraction treatment and sucralfate-based rectal ointment on hemorrhoidal disease: A case-matched analysis.
Humans
Sucralfate
/ therapeutic use
Male
Female
Middle Aged
Prospective Studies
Ointments
Hemorrhoids
Case-Control Studies
Treatment Outcome
Flavonoids
/ administration & dosage
Preoperative Care
/ methods
Adult
Quality of Life
Aged
Administration, Rectal
Severity of Illness Index
Plant Extracts
/ administration & dosage
Flavonoids
Hemorrhoidal disease
Preoperative treatment
Rectal ointment
Sucralfate
Symptom severity
Journal
Techniques in coloproctology
ISSN: 1128-045X
Titre abrégé: Tech Coloproctol
Pays: Italy
ID NLM: 9613614
Informations de publication
Date de publication:
17 Sep 2024
17 Sep 2024
Historique:
received:
05
04
2024
accepted:
09
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
Hemorrhoidal disease (HD) significantly impacts patients' quality of life. This study aimed to evaluate the effectiveness of preoperative treatment with the micronized purified flavonoid fraction (MPFF) and a sucralfate-based rectal ointment in managing HD symptoms and reducing interventions. A prospective quasi-experimental study including consecutive cases and controls matched on the basis of sex was performed in a tertiary referral center. Cases received systemic and local therapy for HD, consisting of a rectal ointment containing 3% sucralfate and herbal extracts plus MPFF, in addition to conservative therapy, while controls received conservative therapy alone. The hemorrhoidal disease symptom score (HDSS), the Short Health Scale for HD (SHS-HD) score, and the Vaizey Incontinence Score were used to evaluate symptoms severity and their impact on quality of life and continence. Intervention requirements were assessed at baseline (T0) and after 60 days of treatment (T1). Between January and December 2023, a total of 98 patients were assessed for eligibility. After exclusions, 56 patients were enrolled, with 28 in each group. Significant improvements were observed in HD symptom scores from T0 to T1: the intervention group showed a mean change in HDSS of -9 [95% confidence interval (CI) -10 to -8], and the control group showed no significant change (mean change of 0; 95% CI -1.5 to 0). At T1, a higher proportion of patients in the intervention group underwent less invasive interventions compared with controls (18% versus 11%). Age, treatment group, and baseline symptom severity significantly predicted post-treatment symptom scores. In our study the preoperative treatment with MPFF and a sucralfate-based rectal ointment demonstrated clinical benefits in managing HD symptoms and reducing interventions. Further prospective trials are warranted to confirm and explore additional therapeutic strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Hemorrhoidal disease (HD) significantly impacts patients' quality of life. This study aimed to evaluate the effectiveness of preoperative treatment with the micronized purified flavonoid fraction (MPFF) and a sucralfate-based rectal ointment in managing HD symptoms and reducing interventions.
METHODS
METHODS
A prospective quasi-experimental study including consecutive cases and controls matched on the basis of sex was performed in a tertiary referral center. Cases received systemic and local therapy for HD, consisting of a rectal ointment containing 3% sucralfate and herbal extracts plus MPFF, in addition to conservative therapy, while controls received conservative therapy alone. The hemorrhoidal disease symptom score (HDSS), the Short Health Scale for HD (SHS-HD) score, and the Vaizey Incontinence Score were used to evaluate symptoms severity and their impact on quality of life and continence. Intervention requirements were assessed at baseline (T0) and after 60 days of treatment (T1).
RESULTS
RESULTS
Between January and December 2023, a total of 98 patients were assessed for eligibility. After exclusions, 56 patients were enrolled, with 28 in each group. Significant improvements were observed in HD symptom scores from T0 to T1: the intervention group showed a mean change in HDSS of -9 [95% confidence interval (CI) -10 to -8], and the control group showed no significant change (mean change of 0; 95% CI -1.5 to 0). At T1, a higher proportion of patients in the intervention group underwent less invasive interventions compared with controls (18% versus 11%). Age, treatment group, and baseline symptom severity significantly predicted post-treatment symptom scores.
CONCLUSIONS
CONCLUSIONS
In our study the preoperative treatment with MPFF and a sucralfate-based rectal ointment demonstrated clinical benefits in managing HD symptoms and reducing interventions. Further prospective trials are warranted to confirm and explore additional therapeutic strategies.
Identifiants
pubmed: 39287845
doi: 10.1007/s10151-024-02998-0
pii: 10.1007/s10151-024-02998-0
doi:
Substances chimiques
Sucralfate
54182-58-0
Ointments
0
Flavonoids
0
Plant Extracts
0
Types de publication
Journal Article
Evaluation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
126Informations de copyright
© 2024. The Author(s).
Références
Gallo G, Sacco R, Sammarco G (2018) Epidemiology of hemorrhoidal disease. In: Ratto C, Parello A, Litta F (eds) Hemorrhoids Coloproctology, vol 2. Springer, Cham, pp 3–7
Kuiper SZ, Kimman ML, Van Tol RR, Waardenburg SF, Van Kuijk SMJ, Dirksen CD, Breukink SO (2022) Patient reported outcome measure-haemorrhoidal impact and satisfaction score (PROM-HISS): development, reliability and construct validity. Colorectal Dis. https://doi.org/10.1111/codi.16079
pubmed: 35398957
pmcid: 9544465
Goligher JC, Duthie HL, Nixon HH (eds) (1984) Surgery of the anus, rectum and colon, 5th edn. Baillière Tindall, London, pp 98–149
Dekker L, Han-Geurts IJM, Grossi U, Gallo G, Veldkamp R (2022) Is the Goligher classification a valid tool in clinical practice and research for hemorrhoidal disease? Tech Coloproctol. https://doi.org/10.1007/s10151-022-02591-3
pubmed: 35141793
pmcid: 9018630
Picciariello A, Tsarkov PV, Papagni V, Efetov S, Markaryan DR, Tulina I, Altomare DF (2021) Classifications and clinical assessment of haemorrhoids: the proctologist’s corner. Rev Recent Clin Trials 16(1):10–16. https://doi.org/10.2174/1574887115666200312163940 . (PMID: 32164517)
pubmed: 32164517
Pata F, Sgró A, Ferrara F, Vigorita V, Gallo G, Pellino G (2021) Anatomy, physiology and pathophysiology of haemorrhoids. Rev Recent Clin Trials 16(1):75–80. https://doi.org/10.2174/1574887115666200406115150
pubmed: 32250229
Alonso-Coello P, Zhou Q, Martinez-Zapata MJ et al (2006) Meta-analysis of flavonoids for the treatment of haemorrhoids. Br J Surg 93:909–920
pubmed: 16736537
Gallo G, Martellucci J, Sturiale A, Clerico G, Milito G, Marino F, Cocorullo G, Giordano P, Mistrangelo M, Trompetto M (2020) Consensus statement of the Italian society of colorectal surgery (SICCR): management and treatment of hemorrhoidal disease. Tech Coloproctol. https://doi.org/10.1007/s10151-020-02149-1
pubmed: 32778974
pmcid: 7416796
Snopkova ́ M, Sukel‘ O and Micanko J, (2023) Effects of a sucralfate-containing ointment on quality of life and symptoms associated with hemorrhoidal disease: patient-reported results of a Slovakian, pharmacist-led observational survey. Front Gastroenterol 2:1213433. https://doi.org/10.3389/fgstr.2023.1213433
Giua C, Minerba L, Piras A, Floris N, Romano F, Sifac G (2021) The effect of sucralfate-containing ointment on quality of life in people with symptoms associated with haemorrhoidal disease and its complications: the results of the EMOCARE survey. Acta Biomed 92(1):e2021029. https://doi.org/10.23750/abm.v92i1.11309
pubmed: 33683221
pmcid: 7975930
Gallese N (2022) Treatment protocol of the most common anorectal pathologies with association between micronized purified flavonoid fraction and sucralfate for local application. Japanese J Gstro Hepato. 8(2):1–3
Amaturo A, Meucci M, Mari FS (2020) Treatment of haemorrhoidal disease with micronized purified flavonoid fraction and sucralfate ointment. Acta Biomed 91(1):139–141. https://doi.org/10.23750/abm.v91i1.9361.PMID:32191669;PMCID:PMC7569574
pubmed: 32191669
pmcid: 7569574
von Elm E, Altman DG, Egger M et al (2008) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. https:// doi. org/ 10. 1016/j. jclin epi. 2007. 11. 008
Harris AD, McGregor JC, Perencevich EN, Furuno JP, Zhu J, Peterson DE, Finkelstein J (2006) The use and interpretation of quasi-experimental studies in medical informatics. J Am Med Inform Assoc 13(1):16–23
pubmed: 16221933
pmcid: 1380192
Gallo G, Di Saverio S, Clerico G, Sturiale A, Manigrasso M, Luc AR et al (2020) Mesoglycan for pain control after open excisional HAEMOrrhoidectomy (MeHAEMO): an observational multicentre study on behalf of the italian society of colorectal surgery (SICCR). BMC Surg 20:251
pubmed: 33092570
pmcid: 7583301
Gupta PJ, Heda PS, Kalaskar S, Tamaskar VP (2008) Topical sucralfate decreases pain after hemorrhoidectomy and improves healing: a randomized, blinded, controlled study. Dis Colon Rectum 51(2):231–234. https://doi.org/10.1007/s10350-007-9092-4
pubmed: 18095028
Lyseng-Williamson KA, Perry CM (2003) Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 63(1):71–100. https://doi.org/10.2165/00003495-200363010-00005 . (PMID: 12487623)
pubmed: 12487623
van Tol RR, Kleijnen J, Watson AJM, Jongen J, Altomare DF, Qvist N, Higuero T, Muris JWM, Breukink SO (2020) European Society of ColoProctology: guideline for haemorrhoidal disease. Colorectal Dis 22(6):650–662. https://doi.org/10.1111/codi.14975
pubmed: 32067353
Gallo G, Pietroletti R, Novelli E, Sturiale A, Tutino R, Lobascio P et al (2022) A multicentre, open-label, single-arm phase II trial of the efficacy and safety of sclerotherapy using 3% polidocanol foam to treat second-degree haemorrhoids (SCLEROFOAM). Tech Coloproctol 26:627–636
pubmed: 35334004
pmcid: 8949823
Rorvik HD, Styr K, Ilum L, McKinstry GL, Dragesund T, Campos AH et al (2019) Hemorrhoidal disease symptom score and short health scalehd: new tools to evaluate symptoms and health-related quality of life in hemorrhoidal disease. Dis Colon Rectum 62:333–342
pubmed: 30451751
Vaizey CJ, Carapeti E, Cahill JA, Kamm MA (1999) Prospective comparison of faecal incontinence grading systems. Gut 44:77–80
pubmed: 9862829
pmcid: 1760067
Fu H, Guo W, Zhou B, Liu Y, Gao Y, Li M (2022) Efficacy and safety of micronized purified flavonoid fractions for the treatment of postoperative hemorrhoid complications: a systematic review and meta-analysis. Phytomedicine 104:154244. https://doi.org/10.1016/j.phymed.2022.154244
pubmed: 35752073
Medkova Y, Tulina I, Yudina V, Abdullaev R, Vlada S, Novikov I, Nikonov A, Tsarkov P (2024) Efficacy of micronized purified flavonoid fraction in PoST-hemorrhoidectomy period (MOST Trial): open-label randomized controlled trial. Dis Colon Rectum. https://doi.org/10.1097/DCR.0000000000003211
pubmed: 38380823